BGI Genomics Co., Ltd.

Shenzhen Stock Exchange 300676.SZ

BGI Genomics Co., Ltd. EBITDA Margin for the year ending December 31, 2023: 14.80%

BGI Genomics Co., Ltd. EBITDA Margin is 14.80% for the year ending December 31, 2023, a -33.16% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

BGI Genomics Co., Ltd. EBITDA Margin for the year ending December 31, 2022 was 22.15%, a -29.95% change year over year.
BGI Genomics Co., Ltd. EBITDA Margin for the year ending December 31, 2021 was 31.62%, a -3.88% change year over year.
BGI Genomics Co., Ltd. EBITDA Margin for the year ending December 31, 2020 was 32.90%, a 53.37% change year over year.
BGI Genomics Co., Ltd. EBITDA Margin for the year ending December 31, 2019 was 21.45%, a -19.04% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Shenzhen Stock Exchange: 300676.SZ

BGI Genomics Co., Ltd.

CEO	Mr. Lijian Zhao
IPO Date	July 14, 2017
Location	China
Headquarters	Building No.7
Employees	3,752
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.

Key trends

Past 5 years